In the United States, colorectal cancer (CRC) is the fourth most common cancer diagnosed among men and women and the second leading cause of death from cancer. Optical colonoscopy has been the dominant method for CRC screening in the U.S. to date. But there are other methods that are also recommended by established guidelines. This article compares the costs of CRC screening using computed tomography or optical colonoscopy for commercially insured people in the U.S.
This article was originally published in American Health & Drug Benefits, October 2018 Vol 11, No 7.